Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
نویسندگان
چکیده
Correction After publishing this article [1], we noted mistake in the spelling of co-author Rajesh Mukthavaram's names. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Cite this article as: Jiang et al.: Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
منابع مشابه
Molecular docking study of anti-viral FDA-approved drugs as novel entry and replication Ebola viral inhibitors
Background & Objective: Because of the reported high ability of virulence and the lack of appropriate drug of Ebola virus during the last decades, many investigations have been accomplished regarding discovery and the introduction of anti-Ebola drugs. The aim of this research was the bioinformatical study of entry and replication of Ebola viral inhibition by drug repurposing. Materials & Method...
متن کاملZika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library
Background The recent epidemics of Zika virus (ZIKV) implicated it as the cause of serious and potentially lethal congenital conditions such microcephaly and other central nervous system defects, as well as the development of the Guillain-Barré syndrome in otherwise healthy patients. Recent findings showed that anti-Dengue antibodies are capable of amplifying ZIKV infection by a mechanism simil...
متن کاملDosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
Combining agents has the potential to attenuate resistance in metastatic cancer. However, knowledge of appropriate starting doses for novel drug combinations in clinical trials and practice is lacking. Analysis of 372 published studies was used to ascertain safe starting doses for doublets involving a cytotoxic and targeted agent. Phase I-III adult oncology clinical trial publications (January ...
متن کاملSynergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
BACKGROUND The malignant brain tumour glioblastoma is a devastating disease that remains a therapeutic challenge. MATERIALS AND METHODS Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines...
متن کاملA review of the current research trends in the application of medicinal plants as a source for novel therapeutic agents against Acanthamoeba infections
Acanthamoeba keratitis (AK) is a sight-threating infection of the cornea that mostly affects contact lens wearers. Until now, AK treatment remains very difficult due to the existence of a highly resistant cyst stage in the life cycle of Acanthamoeba which is extremely resistant to most of the available anti-amoebic compounds. Moreover, current treatment of AK is usually based in the combination...
متن کامل